Kracov Quoted in Bloomberg BNA on FDA User Fees

Life Sciences and Healthcare Regulatory co-chair and partner Dan Kracov was quoted in a recent Bloomberg BNA article, which discusses the impact of a new user fee on the "de novo" classification pathway used by medical device companies to quickly get devices on the US market.

» Read the full article (subscription required).